As of 2025-12-20, the EV/EBITDA ratio of Oramed Pharmaceuticals Inc (ORMP) is -5.02. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. ORMP's latest enterprise value is 64.43 mil USD. ORMP's TTM EBITDA according to its financial statements is -12.85 mil USD. Dividing these 2 quantities gives us the above ORMP EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | - | - |
| Forward P/E multiples | - | - |
| Fair Price | - | - |
| Upside | - | - |
| Date | EV/EBITDA |
| 2025-12-19 | -5.02 |
| 2025-12-18 | -5.17 |
| 2025-12-17 | -5.33 |
| 2025-12-16 | -5.48 |
| 2025-12-15 | -5.48 |
| 2025-12-12 | -5.45 |
| 2025-12-11 | -5.34 |
| 2025-12-10 | -4.92 |
| 2025-12-09 | -4.24 |
| 2025-12-08 | -4.27 |
| 2025-12-05 | -4.27 |
| 2025-12-04 | -4.37 |
| 2025-12-03 | -4.37 |
| 2025-12-02 | -4.46 |
| 2025-12-01 | -4.46 |
| 2025-11-28 | -4.77 |
| 2025-11-26 | -4.77 |
| 2025-11-25 | -4.86 |
| 2025-11-24 | -3.96 |
| 2025-11-21 | -3.93 |
| 2025-11-20 | -3.44 |
| 2025-11-19 | -3.67 |
| 2025-11-18 | -3.65 |
| 2025-11-17 | -3.19 |
| 2025-11-14 | -3.16 |
| 2025-11-13 | -3.37 |
| 2025-11-12 | -3.59 |
| 2025-11-11 | -3.44 |
| 2025-11-10 | -3.00 |
| 2025-11-07 | -2.72 |
| 2025-11-06 | -2.75 |
| 2025-11-05 | -2.88 |
| 2025-11-04 | -3.00 |
| 2025-11-03 | -3.25 |
| 2025-10-31 | -3.34 |
| 2025-10-30 | -3.37 |
| 2025-10-29 | -3.28 |
| 2025-10-28 | -3.25 |
| 2025-10-27 | -3.28 |
| 2025-10-24 | -3.34 |
| 2025-10-23 | -3.28 |
| 2025-10-22 | -3.03 |
| 2025-10-21 | -3.19 |
| 2025-10-20 | -3.03 |
| 2025-10-17 | -2.85 |
| 2025-10-16 | -2.97 |
| 2025-10-15 | -2.97 |
| 2025-10-14 | -3.25 |
| 2025-10-13 | -3.41 |
| 2025-10-10 | -3.41 |